Johnson & Johnson said Tuesday it would proactively delay its vaccine rollout in the European Union following reports of rare but severe cases of blood clots in people who received the shot.

Key Facts

The move came after the U.S. Centers for Disease Control and the Food and Drug Administration recommended a pause in distribution of the Johnson & Johnson vaccine while regulators investigated six cases of unusual blood clots in recipients.

Nearly 7 million doses of the single-shot Johnson & Johnson vaccine have been administered in the U.S. so far, according to the CDC. 

Crucial Quote

“We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine,” Johnson & Johnson said in a statement.